← Back to Search

Targeted Therapy

Targeted Therapy for Advanced Rare Cancers (PREDiCTc Trial)

N/A

Recruiting

Led By Cheryl Ho, MD

Research Sponsored by British Columbia Cancer Agency

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG 0-2

Subject age greater than or equal to 18 years at the time of signature of informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline until death up to 5 years

Awards & highlights

PREDiCTc Trial Summary

This trial aims to assess the quality of life and survival of patients treated with targeted therapy for advanced rare cancers. The goal is to generate real world evidence to support decision making throughout the life cycle of the product.

Who is the study for?

This trial is for adults over 18 with advanced rare cancers or those with uncommon molecular changes, who are expected to live at least 12 weeks. They must be on a Health Canada approved targeted therapy not covered by national funding, have stable brain metastases if present, and be physically able to undergo treatment (ECOG 0-2). Participants need functioning major organs and the ability to consent.Check my eligibility

What is being tested?

The PREDiCTc trial is evaluating the quality of life and survival rates in patients using targeted therapies for rare cancers. These treatments have some evidence of working but aren't widely funded due to their novelty. The study uses CT imaging and Quality of Life (QOL) assessments as tools.See study design

What are the potential side effects?

While specific side effects are not listed, targeted therapies can include fatigue, skin reactions, nausea, liver issues among others depending on the drug used. Side effects will vary based on individual patient factors and the particular therapy administered.

PREDiCTc Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am able to care for myself and move around.

Select...

I am 18 years old or older.

PREDiCTc Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline until death up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline until death up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline until death up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall survival from initiation of targeted therapy

Secondary outcome measures

Progression free survival (PFS) from initiation of targeted therapy

Quality adjusted survival from initiation of targeted therapy

Quality of life (QoL) assessments using the EQ-5D every 8 weeks from initiation of targeted therapy

+2 more

PREDiCTc Trial Design

1Treatment groups

Experimental Treatment

Group I: Targeted therapyExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CT imaging

2020

N/A

~1020

QOL

2001

N/A

~30

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor

171 Previous Clinical Trials

90,481 Total Patients Enrolled

Cheryl Ho, MDPrincipal InvestigatorBC Cancer

4 Previous Clinical Trials

1,641 Total Patients Enrolled

Media Library

Targeted Therapy (Targeted Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04814095 — N/A

Cancer Research Study Groups: Targeted therapy

Cancer Clinical Trial 2023: Targeted Therapy Highlights & Side Effects. Trial Name: NCT04814095 — N/A

Targeted Therapy (Targeted Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04814095 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are engaged in this clinical investigation?

"Affirmative. The clinical trial information on clinicaltrials.gov implies that enrollment is still ongoing for this research study, which was first posted June 30th 2021. As of right now, the project requires 30 individuals to be recruited from one particular medical facility."

Answered by AI

Is enrollment open for this research project?

"Indeed, this clinical trial is actively enrolling participants. The initial posting of the study was on June 30th 2021 and it has since been updated as recent as July 12th 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc

2021. "PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04814095.